Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

Blood·2026

Same author

Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy.

Blood advances·2026

Same author

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Blood advances·2026

Same author

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Blood·2026

Same author

Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.

Leukemia·2026

Same author

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

Blood cancer discovery·2026

Same journal

Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.

Blood cancer discovery·2026

Same journal

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Blood cancer discovery·2026

Same journal

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026

Same journal

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026

Same journal

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Total (Immuno)Therapy: Version 2.0.

Susan Bal^1,2, Luciano J Costa^1,2

¹Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

Blood Cancer Discovery

|November 26, 2024

Summary

This summary is machine-generated.

Autologous chimeric antigen receptor T-cell therapy shows great promise for patients with poly-refractory myeloma. Combining this therapy with bispecific antibodies offers a new total immunotherapeutic strategy.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Jun 6, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunotherapy
Oncology
Hematology

Background:

Multiple myeloma is a hematologic malignancy with limited treatment options for patients with poly-refractory disease.
Autologous chimeric antigen receptor T-cell therapy has emerged as a promising treatment modality for refractory cancers.

Purpose of the Study:

To explore the potential of autologous chimeric antigen receptor T-cell therapy in poly-refractory myeloma.
To discuss the feasibility of combining chimeric antigen receptor T-cell therapy with bispecific antibodies for a comprehensive immunotherapeutic approach.

Main Methods:

Review of current literature and clinical data on chimeric antigen receptor T-cell therapy in multiple myeloma.
Analysis of the role and integration of bispecific antibodies within an immunotherapeutic strategy.

Main Results:

Autologous chimeric antigen receptor T-cell therapy demonstrates significant potential for patients with poly-refractory myeloma.
The advent of bispecific antibodies makes a combined immunotherapeutic strategy with chimeric antigen receptor T-cell therapy clinically feasible.

Conclusions:

Chimeric antigen receptor T-cell therapy represents a vital advancement for patients with limited treatment options in poly-refractory myeloma.
A combined immunotherapeutic approach utilizing both chimeric antigen receptor T-cell therapy and bispecific antibodies offers a promising future direction for managing refractory multiple myeloma.